In the current study, we hypothesize that tocilizumab could serve as a suitable targeting agent to increase the efficacy of chemotherapy, because we identified that in GC, CAFs, which are well-known contributors to chemotherapeutic resistance, were the major source of IL-6 in the tumor microenvironment. Here, IL6 is linked to gastric cancer.